Immune checkpoint inhibitors revolutionized cancer treatment by removing the brakes on the immune system, but the same mechanism can trigger autoimmune destruction of pancreatic beta cells. Roughly 1 percent of patients receiving checkpoint inhibitors develop autoimmune diabetes, often abruptly and frequently with diabetic ketoacidosis (DKA) at presentation. The median time to onset is around 9 weeks after starting therapy. Treatment requires immediate and lifelong insulin. Baseline glucose monitoring before therapy and periodic checks during treatment help catch cases earlier.
What Are Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block immune checkpoint proteins, allowing the immune system to attack cancer cells. The same loss of immune restraint can occasionally turn against healthy tissues, including pancreatic beta cells.
| Class | Drugs | Examples of Indications |
|---|---|---|
| PD-1 inhibitors | Pembrolizumab, nivolumab, cemiplimab | Melanoma, lung, head and neck, renal, urothelial cancers |
| PD-L1 inhibitors | Atezolizumab, durvalumab, avelumab | Lung, urothelial, breast cancers |
| CTLA-4 inhibitors | Ipilimumab | Melanoma, other combinations |
| LAG-3 inhibitor | Relatlimab | Melanoma in combination with nivolumab |
| Combination regimens | Nivolumab + ipilimumab | Melanoma, renal, others — higher endocrine toxicity |
How Often Does It Happen
- Overall incidence of ICI-induced diabetes is approximately 1 percent across most series
- Slightly higher with combination regimens
- Other endocrine immune-related adverse events are more common — thyroiditis (5 to 15 percent), hypophysitis (1 to 10 percent depending on agent), adrenal insufficiency
- Most cases of ICI diabetes are reported as type 1-like with beta-cell destruction
Why Checkpoint Inhibitors Cause Diabetes
Normally, immune checkpoints prevent T cells from attacking the body’s own tissues. When checkpoint inhibitors block PD-1, PD-L1, or CTLA-4, autoreactive T cells can attack beta cells. Several factors contribute:
- Loss of peripheral tolerance to islet antigens
- Pre-existing genetic risk — HLA types overlapping with classic type 1 diabetes (DR3, DR4)
- Possibly subclinical autoimmunity unmasked by treatment
- Direct attack by cytotoxic T cells on beta cells
The phenotype is similar to fulminant type 1 diabetes described in some Japanese cohorts, with rapid beta-cell loss and frequent DKA at onset.
Timing and Presentation
- Median onset: ~9 weeks after first ICI dose
- Range: days to more than a year after treatment start
- Can occur even after treatment is discontinued
- Often abrupt — patient may go from normal glucose to DKA within days
Common Symptoms at Presentation
- Polyuria, polydipsia, weight loss
- Nausea, vomiting, abdominal pain (often DKA)
- Kussmaul breathing, fruity breath, lethargy
- Fatigue and weakness
- Confusion in severe DKA
Roughly 50 to 70 percent of cases in published series presented with DKA, which is much higher than classic adult-onset type 1 diabetes.
Laboratory Features
| Test | Typical Finding in ICI Diabetes |
|---|---|
| Glucose | Severely elevated, often above 400 mg/dL |
| A1C | Can be only modestly elevated because onset is fast |
| C-peptide | Low or undetectable |
| GAD-65 antibody | Positive in ~30 to 50 percent |
| IA-2 antibody | Positive in a minority |
| ZnT8 antibody | Occasionally positive |
| Ketones | Often elevated (DKA) |
| Bicarbonate | Low in DKA |
A relatively normal A1C with severely elevated glucose suggests a rapid process, supporting the diagnosis of fulminant beta-cell destruction. For background on these antibody tests, see our piece on detection of prediabetes.
Baseline and Monitoring
Before Starting Checkpoint Inhibitor Therapy
- Fasting glucose
- A1C
- Personal and family history of autoimmune disease
- Baseline thyroid function for comparison
During Treatment
- Glucose check at each infusion visit
- A1C every 3 months
- Symptom inquiry at every visit — polyuria, polydipsia, weight loss
- Low threshold for fingerstick glucose and ketones if symptoms develop
- Patient education on hyperglycemia warning signs
Acute Management
- Inpatient admission for DKA management — fluids, insulin infusion, electrolyte correction, monitoring
- Endocrinology consultation
- Transition to subcutaneous basal-bolus insulin regimen
- Continuous glucose monitor recommended when discharged
- Diabetes education — insulin technique, hypoglycemia recognition, carb counting
- Identification jewelry and emergency glucagon
Long-Term Management
- Lifelong insulin — beta-cell loss is permanent
- Multiple daily injections or insulin pump therapy
- Continuous glucose monitoring is generally appropriate
- Routine diabetes complications screening — eye, kidney, foot, cardiovascular
- Coordinate with oncology team regarding ICI continuation
Should ICI Therapy Continue
- Generally yes — diabetes is manageable with insulin and does not require ICI discontinuation
- Decisions are individualized between oncology and endocrinology
- Other immune-related events may influence overall risk-benefit balance
- The cancer benefit usually outweighs further endocrine risk
Other Endocrine Immune-Related Adverse Events
| Condition | Approximate Frequency | Reversibility |
|---|---|---|
| Thyroiditis / hypothyroidism | 5 to 15 percent | Often persistent |
| Hypophysitis | 1 to 10 percent (CTLA-4 higher) | Often persistent |
| Primary adrenal insufficiency | Less than 1 percent | Often persistent |
| Diabetes (autoimmune) | ~1 percent | Not reversible |
Patient Education Points
- Report increased thirst, frequent urination, unexplained weight loss promptly
- Carry sick-day instructions if diagnosed
- Know DKA warning signs — nausea, abdominal pain, deep breathing, fruity breath
- Maintain regular oncology follow-up and bring glucose data
- Wear medical identification if on insulin
Related Reading
See our companion pieces on COVID and diabetes, beta cells and diabetes, and the complications hub.
The Bottom Line
Immune checkpoint inhibitors used to treat melanoma, lung cancer, and other malignancies can trigger fulminant autoimmune destruction of pancreatic beta cells in about 1 percent of patients. Onset is often abrupt, with median onset around 9 weeks after starting therapy, and roughly half of cases present with DKA. Treatment requires immediate and lifelong insulin. Baseline glucose and A1C monitoring before and during therapy help catch cases earlier. Oncology and endocrinology teams work together to manage glycemic care without unnecessary interruption of cancer treatment. Patients on checkpoint inhibitors should report any new thirst, urination, or weight loss to their care team promptly.
